Subscribe To
Medivir to report new and updated data from ongoing phase 2a hcc study as part of its q3 report on friday
Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET STOCKHOLM , Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a ph...
October 25, 2023, 2:46 am
Make this breast cancer awareness month about more than awareness with accarent health
Accarent and Keck Medicine of USC partner to bring access to expanded breast cancer bundled procedures ...
October 24, 2023, 6:38 pm
Ambrx: next-generation antibody-drug conjugates, buying the dip after esmo data
Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting...
October 24, 2023, 11:23 am
Bull of the day: neogenomics (neo)
NeoGenomics ( NEO ) is a small-cap provider of cancer genetics diagnostics. They boast one of the most ...
October 24, 2023, 6:46 am
Ambrx biopharma: potential with recently released prostate cancer data
Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with cohorts 6 through 8. I...
October 23, 2023, 6:50 pm
Why revolution medicines stock is crashing today
Revolution Medicines reported data from a phase 1 study of RMC-6236 in treating lung cancer and pancrea...
October 23, 2023, 12:04 pm
Harpoon therapeutics stock soars on ‘promising' lung cancer drug results
Harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinical-stage immunotherapy company announced that it...
October 23, 2023, 9:32 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Merck discontinues some cancer drug development with china's sichuan kelun
Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate ...
October 23, 2023, 3:47 am
Astrazeneca gains european approval for lung cancer drug
AstraZeneca PLC (LSE:AZN) has announced that its jointly developed lung cancer drug has been approved f...
October 23, 2023, 2:57 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...
October 22, 2023, 10:01 am